Societal challenges of precision medicine: Bringing order to chaos

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Societal challenges of precision medicine : Bringing order to chaos. / Salgado, Roberto; Moore, Helen; Martens, John W M; Lively, Tracy; Malik, Shakun; McDermott, Ultan; Michiels, Stefan; Moscow, Jeffrey A.; Tejpar, Sabine; McKee, Tawnya; Lacombe, Denis; Becker, Robert; Beer, Philip; Bergh, Jonas; Bogaerts, Jan; Dovedi, Simon; Fojo, Antonio T.; Gerstung, Moritz; Golfinopoulos, Vassilis; Hewitt, Stephen M.; Hochhauser, Daniel; Juhl, Hartmut; Kinders, Robert; Lillie, Thomas; Herbert, Kim Lyerly; Maheswaran, Shyamala; Mesri, Mehdi; Nagai, Sumimasa; Norstedt, Irene; O'Connor, Daniel; Oliver, Kathy; Oyen, Wim J.G.; Pignatti, Francesco; Polley, Eric; Rosenfeld, Nitzan; Schellens, Jan; Schilsky, Richard; Schneider, Erasmus; Senderowicz, Adrian; Tenhunen, Olli; van Dongen, Augustinus; Vietz, Christine; Wilking, Nils.

I: European Journal of Cancer, Vol. 84, 01.10.2017, s. 325-334.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Salgado, R, Moore, H, Martens, JWM, Lively, T, Malik, S, McDermott, U, Michiels, S, Moscow, JA, Tejpar, S, McKee, T, Lacombe, D, Becker, R, Beer, P, Bergh, J, Bogaerts, J, Dovedi, S, Fojo, AT, Gerstung, M, Golfinopoulos, V, Hewitt, SM, Hochhauser, D, Juhl, H, Kinders, R, Lillie, T, Herbert, KL, Maheswaran, S, Mesri, M, Nagai, S, Norstedt, I, O'Connor, D, Oliver, K, Oyen, WJG, Pignatti, F, Polley, E, Rosenfeld, N, Schellens, J, Schilsky, R, Schneider, E, Senderowicz, A, Tenhunen, O, van Dongen, A, Vietz, C & Wilking, N 2017, 'Societal challenges of precision medicine: Bringing order to chaos', European Journal of Cancer, vol. 84, s. 325-334. https://doi.org/10.1016/j.ejca.2017.07.028

APA

Salgado, R., Moore, H., Martens, J. W. M., Lively, T., Malik, S., McDermott, U., ... Wilking, N. (2017). Societal challenges of precision medicine: Bringing order to chaos. European Journal of Cancer, 84, 325-334. https://doi.org/10.1016/j.ejca.2017.07.028

CBE

Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D, Becker R, Beer P, Bergh J, Bogaerts J, Dovedi S, Fojo AT, Gerstung M, Golfinopoulos V, Hewitt SM, Hochhauser D, Juhl H, Kinders R, Lillie T, Herbert KL, Maheswaran S, Mesri M, Nagai S, Norstedt I, O'Connor D, Oliver K, Oyen WJG, Pignatti F, Polley E, Rosenfeld N, Schellens J, Schilsky R, Schneider E, Senderowicz A, Tenhunen O, van Dongen A, Vietz C, Wilking N. 2017. Societal challenges of precision medicine: Bringing order to chaos. European Journal of Cancer. 84:325-334. https://doi.org/10.1016/j.ejca.2017.07.028

MLA

Vancouver

Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U et al. Societal challenges of precision medicine: Bringing order to chaos. European Journal of Cancer. 2017 okt 1;84:325-334. https://doi.org/10.1016/j.ejca.2017.07.028

Author

Salgado, Roberto ; Moore, Helen ; Martens, John W M ; Lively, Tracy ; Malik, Shakun ; McDermott, Ultan ; Michiels, Stefan ; Moscow, Jeffrey A. ; Tejpar, Sabine ; McKee, Tawnya ; Lacombe, Denis ; Becker, Robert ; Beer, Philip ; Bergh, Jonas ; Bogaerts, Jan ; Dovedi, Simon ; Fojo, Antonio T. ; Gerstung, Moritz ; Golfinopoulos, Vassilis ; Hewitt, Stephen M. ; Hochhauser, Daniel ; Juhl, Hartmut ; Kinders, Robert ; Lillie, Thomas ; Herbert, Kim Lyerly ; Maheswaran, Shyamala ; Mesri, Mehdi ; Nagai, Sumimasa ; Norstedt, Irene ; O'Connor, Daniel ; Oliver, Kathy ; Oyen, Wim J.G. ; Pignatti, Francesco ; Polley, Eric ; Rosenfeld, Nitzan ; Schellens, Jan ; Schilsky, Richard ; Schneider, Erasmus ; Senderowicz, Adrian ; Tenhunen, Olli ; van Dongen, Augustinus ; Vietz, Christine ; Wilking, Nils. / Societal challenges of precision medicine : Bringing order to chaos. I: European Journal of Cancer. 2017 ; Vol. 84. s. 325-334.

RIS

TY - JOUR

T1 - Societal challenges of precision medicine

T2 - European Journal of Cancer

AU - Salgado, Roberto

AU - Moore, Helen

AU - Martens, John W M

AU - Lively, Tracy

AU - Malik, Shakun

AU - McDermott, Ultan

AU - Michiels, Stefan

AU - Moscow, Jeffrey A.

AU - Tejpar, Sabine

AU - McKee, Tawnya

AU - Lacombe, Denis

AU - Becker, Robert

AU - Beer, Philip

AU - Bergh, Jonas

AU - Bogaerts, Jan

AU - Dovedi, Simon

AU - Fojo, Antonio T.

AU - Gerstung, Moritz

AU - Golfinopoulos, Vassilis

AU - Hewitt, Stephen M.

AU - Hochhauser, Daniel

AU - Juhl, Hartmut

AU - Kinders, Robert

AU - Lillie, Thomas

AU - Herbert, Kim Lyerly

AU - Maheswaran, Shyamala

AU - Mesri, Mehdi

AU - Nagai, Sumimasa

AU - Norstedt, Irene

AU - O'Connor, Daniel

AU - Oliver, Kathy

AU - Oyen, Wim J.G.

AU - Pignatti, Francesco

AU - Polley, Eric

AU - Rosenfeld, Nitzan

AU - Schellens, Jan

AU - Schilsky, Richard

AU - Schneider, Erasmus

AU - Senderowicz, Adrian

AU - Tenhunen, Olli

AU - van Dongen, Augustinus

AU - Vietz, Christine

AU - Wilking, Nils

PY - 2017/10/1

Y1 - 2017/10/1

N2 - The increasing number of drugs targeting specific proteins implicated in tumourigenesis and the commercial promotion of relatively affordable genome-wide analyses has led to an increasing expectation among patients with cancer that they can now receive effective personalised treatment based on the often complex genomic signature of their tumour. For such approaches to work in routine practice, the development of correspondingly complex biomarker assays through an appropriate and rigorous regulatory framework will be required. It is becoming increasingly evident that a re-engineering of clinical research is necessary so that regulatory considerations and procedures facilitate the efficient translation of these required biomarker assays from the discovery setting through to clinical application. This article discusses the practical requirements and challenges of developing such new precision medicine strategies, based on leveraging complex genomic profiles, as discussed at the Innovation and Biomarkers in Cancer Drug Development meeting (8th–9th September 2016, Brussels, Belgium).

AB - The increasing number of drugs targeting specific proteins implicated in tumourigenesis and the commercial promotion of relatively affordable genome-wide analyses has led to an increasing expectation among patients with cancer that they can now receive effective personalised treatment based on the often complex genomic signature of their tumour. For such approaches to work in routine practice, the development of correspondingly complex biomarker assays through an appropriate and rigorous regulatory framework will be required. It is becoming increasingly evident that a re-engineering of clinical research is necessary so that regulatory considerations and procedures facilitate the efficient translation of these required biomarker assays from the discovery setting through to clinical application. This article discusses the practical requirements and challenges of developing such new precision medicine strategies, based on leveraging complex genomic profiles, as discussed at the Innovation and Biomarkers in Cancer Drug Development meeting (8th–9th September 2016, Brussels, Belgium).

KW - Assay validation

KW - Biomarkers

KW - Drug development

KW - Preanalytical and analytical validation

KW - Precision oncology

KW - Regulatory sciences

UR - http://www.scopus.com/inward/record.url?scp=85028944052&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2017.07.028

DO - 10.1016/j.ejca.2017.07.028

M3 - Article

VL - 84

SP - 325

EP - 334

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 1879-0852

ER -